Downloadable Summary Resource

HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.

Mark D. Pegram, MD
Program Director

Michael F. Press, MD, PhD

Downloadable Summary Resource

PDF

Clinical Pocket Guide: Diagnostic Testing for HER2, HER3, and TROP2 and Treatment Implications in Breast, GI, and Lung Cancers

View PDF

Download this PDF summarizing key points in HER2, HER3, and TROP2 testing and targeted therapy for patients with breast, GI, and lung cancers.

Mark D. Pegram, MD
Program Director

Michael F. Press, MD, PhD Released: July 30, 2020

HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Clinical Pocket Guide: Diagnostic Testing for HER2, HER3, and TROP2 and Treatment Implications in Breast, GI, and Lung Cancers

Leaving the CCO site